Table 3. Stratified analyses of the −592C > A and −1082G > A polymorphisms in IL-10 gene with colorectal cancer and hepatocellular carcinoma risk under the dominant model.
| |
−592C > A polymorphism |
Subgroup | −1082G > A polymorphism |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subgroup | Num. of studies | OR | 95% CI | P | I2 | Num. of studies | OR | 95% CI | P | I2 | ||
| Colorectal cancer | ||||||||||||
| Ethnicity | East Asian | 1 | —* | — | — | — | Caucasian | 9 | 1.07 | 0.92–1.24 | 0.378 | 0.0% |
| Caucasian | 9 | 1.00 | 0.91–1.11 | 0.986 | 4.5% | Mixed | 2 | 0.64 | 0.43–0.95 | 0.028 | 0.0% | |
| Matched | YES | 5 | 1.02 | 0.87–1.19 | 0.841 | 0.0% | YES | 7 | 0.98 | 0.83–1.16 | 0.821 | 31.4% |
| Source | Population | 9 | 1.02 | 0.92–1.12 | 0.775 | 12.7% | Population | 8 | 1.05 | 0.90–1.22 | 0.575 | 0.0% |
| Hospital | 1 | — | — | — | — | Hospital | 3 | 0.83 | 0.59–1.16 | 0.268 | 28.7% | |
| Study design | Retrospective | 6 | 1.21 | 1.00–1.45 | 0.047 | 0.0% | Retrospective | 8 | 0.95 | 0.78–1.15 | 0.583 | 0.0% |
| Nested | 4 | 0.94 | 0.84–1.06 | 0.323 | 0.0% | Nested | 3 | 1.07 | 0.87–1.30 | 0.531 | 38.3% | |
| HWE | YES | 10 | 1.01 | 0.92–1.12 | 0.830 | 3.6% | YES | 9 | 1.04 | 0.89–1.20 | 0.655 | 0.0% |
| Sample size | <300 | 3 | 1.05 | 0.77–1.43 | 0.776 | 0.0% | <300 | 4 | 0.90 | 0.64–1.27 | 0.553 | 0.0% |
| ≥300 | 7 | 1.01 | 0.91–1.12 | 0.895 | 30.7% | ≥300 | 7 | 1.03 | 0.88–1.19 | 0.751 | 26.6% | |
| Hepatocellular carcinoma | ||||||||||||
| Ethnicity | East Asian | 7 | 0.95 | 0.67–1.36 | 0.794 | 59.3% | East Asian | 5 | 0.85 | 0.25–2.85 | 0.786 | 0.0% |
| Caucasian | 0 | — | — | — | — | Caucasian | 1 | — | — | — | — | |
| Matched | YES | 2 | 1.40 | 1.00–1.97 | 0.048 | 0.0% | YES | 3 | 0.66 | 0.28–1.57 | 0.350 | 0.0% |
| NO | 3 | 1.09 | 0.71–1.67 | 0.696 | 21.9% | NO | 2 | 0.48 | 0.08–2.95 | 0.425 | 0.0% | |
| Source | Population | 2 | 1.01 | 0.61–1.68 | 0.969 | 0.0% | Population | 3 | 0.61 | 0.26–1.45 | 0.266 | 0.0% |
| Hospital | 5 | 0.93 | 0.58–1.49 | 0.774 | 72.3% | Hospital | 3 | 0.98 | 0.25–3.86 | 0.977 | 0.0% | |
| Study design | Retrospective | 6 | 0.96 | 0.64–1.46 | 0.864 | 66.0% | Retrospective | 5 | 0.73 | 0.34–1.54 | 0.402 | 0.0% |
| Nested | 1 | — | — | — | — | Nested | 1 | — | — | — | — | |
| HWE | YES | 4 | 0.82 | 0.50–1.36 | 0.449 | 74.3% | YES | 4 | 0.70 | 0.32–1.55 | 0.381 | 0.0% |
| Sample size | <300 | 3 | 1.25 | 0.77–2.03 | 0.364 | 4.6% | <300 | 3 | 0.62 | 0.26–1.45 | 0.268 | 0.0% |
| ≥300 | 4 | 0.85 | 0.53–1.36 | 0.504 | 73.9% | ≥300 | 3 | 0.98 | 0.24–4.00 | 0.980 | 0.0% | |
Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; HWE, Hardy-Weinberg equilibrium. P value was calculated under the random-effects model adopting the DerSimonian and Laird method. *Data are not shown due to the limited number of qualified articles (n < 2).